Stockreport

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditionin...

Achilles Therapeutics plc - American Depositary Shares  (ACHL) 
PDF – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expe [Read more]